Darbepoetin alfa: all 123 studies that test it
Page 2 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate Effectiveness of Aranesp®CompletedNCT00117130Phase 4
- A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®CompletedNCT00117117Phase 4
- Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic HemodialysisCompletedNCT00117104Phase 4
- Aranesp® Monthly Preference Study - 2CompletedNCT00117078Phase 4
- Study of Transplant Related Anemia Treated With Aranesp® (STRATA)CompletedNCT00117065Phase 4
- A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With AnemiaCompletedNCT00117039Phase 4
- Treatment for Subjects With Chronic Kidney Disease Receiving HaemodialysisCompletedNCT00116701Phase 3
- A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 StudyCompletedNCT00115167Phase 3
- Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving HemodialysisCompletedNCT00111995Phase 4
- Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle ChemotherapyCompletedNCT00111462Phase 2
- Treatment for Patients With Non-Myeloid Malignancies Receiving ChemotherapyCompletedNCT00111137Phase 3
- Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving DialysisCompletedNCT00111098Phase 3
- Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00110955Phase 3
- Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving DialysisCompletedNCT00096915Phase 3
- Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of CancerCompletedNCT00095277Phase 2
- A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic SyndromeCompletedNCT00095264Phase 2
- Study of Darbepoetin Alfa for the Treatment of Anemia of CancerCompletedNCT00091858Phase 3
- Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & AnemiaCompletedNCT00086086Phase 2
- Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
- Heart Failure and AnemiaCompletedNCT00049985Phase 2
- Anemia in Patients With a Non-Myeloid MalignancyCompletedNCT00038064Phase 3
- Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesCompletedNCT00036023Phase 2
- Chemotherapy Related AnemiaCompletedNCT00035607Phase 2